ArticleOncoimmunology
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
Yusuke Tomita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
trialcites it